B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention

Acta Radiologica

Volumn 51, Issue 6, 2010, Pages 641-648

  Zhang, Jing ^a   Fu, Xianghua ^a   Jia, Xinwei ^a   Fan, Xinna ^b   Gu, Xinshun ^a   Li, Shiqiang ^a   Wu, Weili ^a   Fan, Weize ^a   Su, Jianling ^a   Hao, Guozhen ^a   Jiang, Yunfa ^a   Xue, Ling ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI GENERAL HOSPITAL   (China)

Author keywords

Glomerular filtration rate; Renal failure; Serum creatinine

Indexed keywords

ACUTE MYOCARDIAL INFARCTION; B-TYPE NATRIURETIC PEPTIDE; CONTROL GROUPS; GLOMERULAR FILTRATION RATE; HEART FAILURE; NEPHROPATHY; PEAK VALUES; PERCUTANEOUS CORONARY INTERVENTION; PROTECTIVE EFFECTS; RANDOMIZED TRIAL; RENAL DISEASE; RENAL FAILURE; RENAL FUNCTIONS;

BODY FLUIDS; HOSPITALS; PEPTIDES;

HEART;

BRAIN NATRIURETIC PEPTIDE; CONTRAST MEDIUM; CREATININE; PROTECTIVE AGENT;

AGED; ANGIOPLASTY; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; KIDNEY DISEASE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

AGED; ANGIOPLASTY; CONTRAST MEDIA; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROTECTIVE AGENTS;

EID: 77953349558     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.3109/02841851.2010.486804     Document Type: Article

References (36)

1. Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lansky AJ, et al. Impact of renal insuf fi ciency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003;108:2769-2775
2. Thomsen HS, Morcos SK, Barrett BJ. Contrast-induced nephropathy: the wheel has turned 360 degrees. Acta Radiol 2008;49:646-657
3. Lindsay J, Canos DA, Apple S, Pinnow E, Aggrey GK, Pichard AD. Causes of acute renal dysfunction after percutaneous coronary intervention and comparison of late mortality rates with postprocedure increase of creatinekinase-MB versus increase of serum creatinine. Am J Cardiol 2004;94:786-789
4. Fishman EK, Reddan D. What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography. Acta Radiol 2008;49:310-320
5. Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004;44:1780-1785
6. Morcos SK, Thomsen HS, Webb JA. Contrast-mediainduced nepheotoxicity; a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur J Radiol 1999;9:1602-1613
7. Thomsen HS, Hemmingsen L, Dorph S, Skaarup P. Effects on urine profiles of diatrizoate in hydrated and dehydrated rats. Acta Radiol 1988;29:731-735
8. Birck R, Krzossok S, Markowetz F, Schnulle P, Van Der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy; meta-analysis. Lancet 2003;362:598-603.
9. Duan SB, Wang YH, Liu FY, Xu XQ, Wang P, Zou Q, et al. The protective role of Telmisartan against nephrotoxicity induced by X-ray contrast media in rat model. Acta Radiol 2009;50:754-759
10. From AM, Bartholmai BJ, Williams AW, McDonald FS. Iodixanol compared to iohexol for contrast procedures: a case-matched retrospective cohort study. Acta Radiol 2008;49:409-414
11. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329-336
12. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000;343:246-253
13. The VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287: 1531-1540
14. Brunner-La Rocca HP, Kaye DM, Woods RL, Hastings J, Esler MD. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001;37:1221-1227
15. Burger AJ. A review of the renal and neurohormonal effects of B-type natriuretic peptide. Congest Heart Fail 2005;11:30-38
16. Marcus LS, Hart D, Packer M, Medina N, Danziger RS, Heitjan DF, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1996; 94:3184-3189
17. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-328
18. Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993;76:91-96
19. Molina CR, Fowler MB, McCrory S, Peterson C, Myers BD, Schroeder JS, et al. Hemodynamic, renal and endocrine effects of atrial natriuretic peptide infusion in severe heart failure. J Am Coll Cardiol 1988;12:175-186
20. Hillock RJ, Frampton CM, Yandle TG, Troughton RW, Lainchbury JG, Richards AM. B-type natriuretic peptide infusions in acute myocardial infarction. Heart 2008;94: 617-622
21. Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001;37:1820-1826
22. Li SQ, Fu XH, Liu J, Gu X, Zhang J, Fan XN, et al. Acute hemodynamic effects of intravenous recombinant human brain natriuretic peptide in patients with acute myocardial infarction complicated with heart failure. Chin J Cardiol 2006;34:23-27
23. Khot UN, Jia G, Moliterno DJ, Lincoff AM, Khot, MB, Harrington RA, et al. Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classifi cation. JAMA 2003;290:2174-2181
24. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modifi cation of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-254
25. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008;51:1419-1428
26. Patti G, Nusca A, Chello M, Pasceri V, D'Ambrosio A, Vetrovec GW, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve longterm outcomes in patients undergoing percutaneous coronary intervention. Am J Cardiol 2008;101:279-285
27. Elkayam U, Akhter MW, Liu M, Hatamizadeh P, Barakat MN. Assessment of renal hemodynamic effects of nesiritide in patients with heart failure using intravascular doppler and quantitative angiography. J Am Coll Cardiol Imag 2009;1:765-771
28. Chen HH, Cataliotti A, Schirger JA, Martin FL, Harstad LK, Burnett JC. Local renal delivery of a natriuretic peptide: a renal-enhancing strategy for B-type natriuretic peptide in overt experimental heart failure. J Am Coll Cardiol 2009;53:1302-1308
29. Jensen KT, Carstens J, Pedersen EB. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol Renal Physiol 1998;274:F63-72.
30. D'Souza SP, Yellon DM, Martin C, Schulz R, Heusch G, Onody A, et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via K ATP channel opening. Am J Physiol Heart Circ Physiol 2003;284:H1592-600.
31. Michaels AD, Klein A, Madden JA, Chatterjee K. Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation 2003;107:2697-2701
32. Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004;147:331-338 (Pubitemid 38176835)
33. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006;97:1759-1764
34. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal functions with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-1491
35. Wang DJ, Dowling TC, Meadows D, Ayala T, Marshall J, Minshall S, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004;110:1620-1625
36. Riter HG, Redfield MM, Burnett JC, Chen HH. Nonhypotensive low-dose Nesiritide has differential renal effects compared with standard-dose Nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol 2006;47:2334-2335